Blood Pressure Target in Acute Stroke to Reduce hemorrhaGe After Endovascular Therapy
NCT ID: NCT03160677
Last Updated: 2021-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
320 participants
INTERVENTIONAL
2017-06-21
2020-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cerebral Autoregulation Guiding Blood Pressure Management After Revascularization
NCT05670028
Intensive Blood Pressure Control in Ischaemic Stroke Patients With Severe Cerebral Small Vessel Disease
NCT05690997
Blood Pressure Control in Acute Ischemic Stroke
NCT03443596
Individualized Blood Pressure Management During Endovascular Stroke Treatment
NCT04578288
Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke
NCT02327793
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* inclusion after reperfusion: clinical evaluation with NIHSS (National Institute of Health Stroke Score) score, measurement of blood pressure.
* within 24 hours after reperfusion: blood pressure measurements
* at 24 hours: measurement of blood pressure (T0 + 24 h and evaluation of the NIHSS score.
* Between 24 and 36 hours :cerebral scan (assessment of hemorrhagic transformations and cerebral infarction volumes). For some centers: Cerebral MRI without injection between H24 and H36
* 72 hours after reperfusion: Cerebral scanner in case of hyperdensity on the initial scanner
* 3 months after reperfusion: disability assessment by Rankin score
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intensive blood pressure management
Systolic blood pressure target < 130 mm Hg
Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 130 mm Hg
Standard blood pressure management
Systolic blood pressure target < 185 mm Hg
Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 185 mm Hg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Systolic blood pressure target < 130 mm Hg
Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 130 mm Hg
Systolic blood pressure target < 185 mm Hg
Adaptation of antihypertensive treatments to reach the Systolic blood pressure target \< 185 mm Hg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Reperfusion after a thrombectomy procedure (defined by a 2b-3 TICI score -Thrombolysis In Cerebral Infarction- score).
Exclusion Criteria
* Systolic blood pressure at baseline \<130 mm Hg within one hour of recanalization
* Pre-existing stroke handicap defined by a Rankin score (modified scale, mRS)\> 3
* Hemodynamically significant carotid stenosis
* Occlusion of the isolated cervical carotid artery
* Known pregnancy
* Legal protection
* Non-affiliation to a social security scheme
* Refusal of the patient (or of his / her relatives in case of urgent inclusion)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Ophtalmologique Adolphe de Rothschild
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mikael MAZIGHI, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Fondation Ophtalmologique A. de Rothschild
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Bordeaux
Bordeaux, , France
Hôpital neurologique Pierre Wertheimer, Hospices Civils de Lyon
Lyon, , France
Centre Hospitalier Régional Universitaire
Nancy, , France
Hopital Lariboisière
Paris, , France
Fondation Ophtalmologique A de Rothschild
Paris, , France
Hopital Foch
Suresnes, , France
Hopital de purpan
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Maier B, Brauner R, Escalard S, Gory B, Lapergue B, Sibon I, Richard S, Labreuche J, Kyheng M, Desilles JP, Blanc R, Piotin M, Halimi JM, Mazighi M; BP-TARGET Trial Investigators. Association of Contrast Enhancement After Reperfusion With Outcomes According to Blood Pressure Lowering in Patients With Acute Ischemic Stroke. Neurology. 2022 Nov 22;99(21):e2385-e2394. doi: 10.1212/WNL.0000000000201173. Epub 2022 Aug 30.
Maier B, Gory B, Lapergue B, Sibon I, Richard S, Kyheng M, Labreuche J, Desilles JP, Blanc R, Piotin M, Mazighi M, Halimi JM; BP TARGET Investigators. Effect of Baseline Antihypertensive Treatments on Stroke Severity and Outcomes in the BP TARGET Trial. Stroke. 2022 Jun;53(6):1837-1846. doi: 10.1161/STROKEAHA.121.037548. Epub 2022 Mar 24.
Anadani M, Maier B, Escalard S, Labreuche J, de Havenon A, Sabben C, Lapergue B, Gory B, Richard S, Sibon I, Desilles JP, Blanc R, Piotin M, Mazighi M; of behalf the BP-TARGET Study Group*. Magnitude of Blood Pressure Change After Endovascular Therapy and Outcomes: Insight From the BP-TARGET Trial. Stroke. 2022 Mar;53(3):719-727. doi: 10.1161/STROKEAHA.121.036701. Epub 2022 Feb 3.
Mazighi M, Richard S, Lapergue B, Sibon I, Gory B, Berge J, Consoli A, Labreuche J, Olivot JM, Broderick J, Duhamel A, Touze E, Qureshi AI, Yavchitz A, Escalard S, Desilles JP, Redjem H, Smajda S, Fahed R, Hebert S, Maier B, Delvoye F, Boursin P, Maacha MB, Obadia M, Sabben C, Blanc R, Savatovsky J, Piotin M; BP-TARGET investigators. Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2021 Apr;20(4):265-274. doi: 10.1016/S1474-4422(20)30483-X. Epub 2021 Feb 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MMI_2016_26
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.